Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9761776 | 0.78 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1PGK1 | |
| SCHEMBL9761403 | 0.70 | ALDH1A1 (0.32) | MAPTALDH1A1 | |
| SCHEMBL9762165 | 0.69 | KMT2A (0.44) | MAPTSMN1; SMN2ALDH1A1GAATDP1 | |
| SCHEMBL9761831 | 0.67 | CCR6 (0.33) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10400450 | 0.64 | MAPT (0.40) | MAPTSMN1; SMN2ALDH1A1PGK1GAA | |
| SCHEMBL9761813 | 0.62 | — | — | |
| SCHEMBL9789043 | 0.60 | PGK1 (0.40) | MAPTSMN1; SMN2ALDH1A1PGK1MAPK8 | |
| SCHEMBL10270164 | 0.59 | PGK1 (0.42) | MAPTALDH1A1PGK1 | |
| SCHEMBL6118560 | 0.58 | TDP1 (0.52) | MAPTSMN1; SMN2ALDH1A1PGK1TDP1 | |
| SCHEMBL11651962 | 0.58 | GAA (0.39) | MAPTSMN1; SMN2ALDH1A1PGK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5026694-A | Antitumor agents | THE BRITISH COLUMBIA CANCER FOUNDATION (CA) | 1991-06-25 | — | — | US | disclosed |